The effects of PPAR gamma agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model

Creative Commons License

Guzeloglu M., REEL B., Atmaca S., BAĞRIYANIK H. A., Hazan E.

JOURNAL OF CARDIOTHORACIC SURGERY, cilt.7, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1186/1749-8090-7-57
  • Dergi Adı: JOURNAL OF CARDIOTHORACIC SURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Neointima, Rosiglitazone, Matrix metalloproteinases (MMPs), Rabbit, MUSCLE-CELL PROLIFERATION, CORONARY-ARTERY-DISEASE, TISSUE INHIBITOR, VASCULAR INJURY, SAPHENOUS-VEIN, IN-VIVO, PTFE GRAFTS, MIGRATION, MATRIX, EXPRESSION
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Neointimal hyperplasia involving smooth muscle cell (SMC) proliferation, migration and extracellular matrix (ECM) degradation is an important component of atherosclerosis. It develops as a response to vascular injury after balloon angioplasty and vascular graft placement. Matrix metalloproteinases (MMPs) induce SMC proliferation, migration and contribute to intimal hyperplasia by degrading ECM. PPAR. agonists inhibit SMC proliferation, migration and lesion formation. In this study, we aimed to investigate the effects of PPAR. agonist rosiglitazone on neointimal hyperplasia and gelatinase (MMP-2 and MMP-9) expressions in rabbit carotid anastomosis model.